With a consistent focus on expanding its international operations, Lavipharm has completed its eighth appearance at CPHI Europe, the pharmaceutical industry’s leading international gathering, held this year in Milan from 6 to 8 October.
Once again, the exhibition brought together the global pharmaceutical ecosystem, with more than 2,900 exhibiting companies, over 62,000 professionals and more than 320 specialist speakers. CPHI has long served as an important meeting place for building business partnerships, exchanging expertise and keeping abreast of developments in the international pharmaceutical market.
According to a company announcement, this year’s presence at CPHI confirmed Lavipharm’s strategic decision to steadily expand its international operations. The company’s expertise and capabilities were in focus, with particular emphasis on transdermal technology. During the exhibition, company executives held substantive meetings with existing and prospective partners from different markets, fostering dialogue on new business opportunities.
Mr Giannis Sarigiannidis, the company’s Chief Commercial Officer International, said: “Our participation in CPHI for the eighth year running once again confirms our steadfast commitment to expanding our international operations.
With a presence in more than 40 countries, we remain firmly focused on international expansion, innovation and creating value through strategic international partnerships that can support Lavipharm’s further growth and strengthen its position in the international pharmaceutical market”.